/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Event: ESC Congress 2023
Topic: Pharmacotherapy
Session: State-of-the art treatment of HFmrEF and HFpEF in 2023
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial
Event: Heart Failure 2023
Topic: Pharmacotherapy
Session: Chronic heart failure - pharmacotherapy 4
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Event: Heart Failure 2023
Topic: Pharmacotherapy
Session: Chronic heart failure - pharmacotherapy 2
Need of Treating Residual Inflammatory Activity in Coronary Heart Disease: the value of high sensitive CRP and LDL in a Real World Cohort.
Event: ESC Congress 2018
Topic: Inflammation and Immunity
Session: Inflammation and immunity in acute coronary syndromes
ESC 365 is supported by
